Unlock instant, AI-driven research and patent intelligence for your innovation.

TFPR1 protein, a coding gene thereof and application thereof in immune regulation

A protein and encoding technology, applied in the biological field, can solve problems such as adverse reactions

Active Publication Date: 2015-05-06
MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These oil / water emulsion adjuvants all have obvious adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TFPR1 protein, a coding gene thereof and application thereof in immune regulation
  • TFPR1 protein, a coding gene thereof and application thereof in immune regulation
  • TFPR1 protein, a coding gene thereof and application thereof in immune regulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1. Obtainment, expression and purification of protein TFPR1 and its encoding gene

[0049] 1. Obtaining the protein TFPR1

[0050] After bioinformatics analysis and prediction, a Triflin functional domain containing 145 amino acid residues was designed, and sequence 1 in the synthetic sequence table was synthesized. The gene shown in it was named TFPR1, and BamHI and Hind were added to the 5' and 3' ends respectively III, entrust Nanjing GenScript Biotechnology Co., Ltd. to synthesize the whole gene, and obtain the cloned plasmid pUC57-TFPR1 (obtained by inserting the TFPR1 shown in sequence 1 in the sequence table between the EcoRV sites of the pUC57 vector).

[0051] The protein encoded by the gene TFPR1 shown in the sequence 1 in the sequence listing is named TFPR1, and the amino acid sequence of the protein is the 13th-157th amino acid from the N-terminal of the sequence 2 in the sequence listing.

[0052] 2. Construction of recombinant vector pET-TFPR1

...

Embodiment 2

[0072] Example 2. Application of TFPR1 as an immunomodulator

[0073] 1. Binding and activation test of TFPR1 and mouse splenocytes

[0074] The spleen of BALB / c mice was isolated under sterile conditions, and the mononuclear cells were isolated, and the binding of protein to spleen mononuclear cells was analyzed by flow cytometry. The specific methods are as follows:

[0075] Adjust the isolated mouse splenocytes to 10×10 6 / ml, add 50 μL to each tube, and add the renatured recombinant protein TFPR1 prepared in 5 of Example 1 with a final concentration of 10 μg / ml, mix well, incubate at room temperature for 30 min, and then wash with phosphate buffered saline (PBS) ( 1500rpm, 6min), and then FITC-labeled anti-His antibody (Miltenyi Biotec) was added.

[0076] The results showed that TFPR1 mainly binds to B cells with antigen-presenting effect in mouse splenocytes ( Figure 4 B) and macrophages ( Figure 4 D), and combined with a part of NK cells ( Figure 4 C), without b...

Embodiment 3

[0084] Example 3. Application of recombinant protein TFPR1 as vaccine adjuvant

[0085] 1. Animal immunization and grouping

[0086] Female BALB / C mice, SPF grade, 5-6 weeks old, were purchased from the Experimental Animal Center of the Academy of Military Medical Sciences, randomly assigned to different experimental groups, and kept in SPF grade animal rooms. Using endotoxin-free ovalbumin OVA, yeast-expressed hepatitis B surface antigen (HBsAg) and HIV-1 polypeptide P5 (PKVSFEPIPIHYCAPAGFAILKCNNKTFN) as model antigens, the adjuvant activity of TFPR1 was observed. The route of inoculation is intramuscular, and the injection volume of each mouse is 200 μL. In all the following studies using aluminum adjuvant as an adjuvant control, the volume ratio of aluminum adjuvant and immunogen is 1:9 according to the optimized dose recommended in the product instructions. .

[0087] (1) Observing the adjuvant activity of TFPR1 with OVA as the model antigen: BALB / c mice aged 5 weeks wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a TFPR1 protein, a coding gene thereof and application thereof in immune regulation. The TFPR1 protein is (a) or (b) or (c) as follows: (a) a protein consisting of an amino acid sequence represented in a sequence 2 in a sequence table; (b) a protein consisting of amino acid sequences from a tail end N to a site (13-157) of the amino acid sequence in the sequence 2 in the sequence table; (c) proteins which are formed by substituting and / or deleting and / or adding the amino acid sequence represented by (a) or (b) by virtue of one or more amino acid residues, have same functions and derived from the amino acid sequence represented by (a) or (b). The invention provides the application of TFPR1 protein and a derivative thereof as an active protein and an adjuvant in the immune regulation. Experiments prove that TFPR1 is the protein with immune regulation activity and is hopeful of being used as a novel adjuvant and applied to the research and production of vaccines.

Description

technical field [0001] The present invention relates to the field of biotechnology, in particular to TFPR1 protein and its encoding gene and its application in immune regulation. Background technique [0002] Vaccination is the most effective way to prevent infectious diseases. Traditional vaccines mainly include live attenuated vaccines and inactivated vaccines, while new vaccines include subunit vaccines, conjugate vaccines, synthetic peptide vaccines, and genetically engineered vaccines. New vaccines have high purity and high specificity, but their molecules are small and their immunogenicity is relatively poor, making it difficult to generate an effective immune response. Adjuvants are needed to enhance their immunogenicity or the host's protective response to antigens. Since the body's protective immune response to different pathogens is different, the development of vaccines that can induce protective responses against different pathogens requires different adjuvants....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/00C12N15/11C12N15/63A61K38/16A61K39/39A61K39/00A61P37/02
CPCA61K39/39A61K2039/55516A61K2039/57C07K14/00
Inventor 寇志华周育森孙维来杨裔郭晶晶于虹郭彦李军锋
Owner MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI